Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.21.2
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
September 30, 2021 December 31, 2020
Current pharma contract assets (1)
$ 1,903  $ 1,643 
Long-term pharma contract assets (2)
248  290 
Total pharma contract assets $ 2,151  $ 1,933 
Current pharma capitalized commissions (1)
$ 126  $ 185 
Long-term pharma capitalized commissions (2)
953  970 
Total pharma capitalized commissions $ 1,079  $ 1,155 
Current pharma contract liabilities $ 5,278  $ 4,029 
Long-term pharma contract liabilities (3)
932  712 
Total pharma contract liabilities $ 6,210  $ 4,741 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
2021 2020 2021 2020
Clinical Services:
    Client direct billing $ 64,195  $ 72,896  $ 188,040  $ 172,431 
    Commercial Insurance 19,539  19,218  58,642  56,360 
    Medicare and Medicaid 18,295  16,460  52,929  46,484 
    Self-Pay 198  159  508  324 
Total Clinical Services $ 102,227  $ 108,733  $ 300,119  $ 275,599 
Pharma Services: 19,113  16,711  58,478  42,852 
Total Revenue $ 121,340  $ 125,444  $ 358,597  $ 318,451